TAK on NYSE

Takeda Pharmaceutical Company

Logo: Takeda Pharmaceutical Company, Public domain, via Wikimedia Commons5

Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire).3 From Wikipedia, CC BY-SA 4.0

$19.64 up 0.62 (3.29%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 16, 2026.

Overview

4.6TRevenue, fiscal 20256
108.1BNet income, fiscal 20256
Aug 1, 1781Founded1

Compare with another stock.

  • TickerTAK on NYSE1
  • Industrypharmaceutical industry1
  • HeadquartersŌsaka-shi1
  • Founded inDoshōmachi1
  • Websitewww.takeda.co.jp
  • Legal formkabushiki gaisha1
  • Listed onFukuoka Stock Exchange (4502), Nagoya Stock Exchange (4502), New York Stock Exchange (TAK), Sapporo Securities Exchange (4502), Tokyo Stock Exchange (4502)1
  • Business address1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo, M0 103-86687
  • Filer categoryLarge accelerated filer7

See how the biggest companies compare on our leaderboards

Takeda global headquarters
Photo: 妖精書士, CC0, via Wikimedia Commons8

The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in JPY, the currency the company reports in.

Key numbers, fiscal 2025

7.5%Operating margin6
2.4%Net margin6
7.5%Revenue growth, 20256
1.6%Return on equity6
856.4B JPYFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs98¢4.5T JPY
  • Profit2¢108.1B JPY

Out of 4.6T JPY in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending19¢200.8B JPY
  • Kept or used elsewhere81¢856.4B JPY

Out of 1.1T JPY of cash from operations.6

Financial statements

Revenue91011121364.6T JPY in 2025+159% since 2018
02.0T JPY4.0T JPY6.0T JPY2018: 1.8T JPY1.8T JPY20182019: 2.1T JPY2.1T JPY2019+18%2020: 3.3T JPY3.3T JPY2020+57%2021: 3.2T JPY3.2T JPY2021−3%2022: 3.6T JPY3.6T JPY2022+12%2023: 4.0T JPY4.0T JPY2023+13%2024: 4.3T JPY4.3T JPY2024+6%2025: 4.6T JPY4.6T JPY2025+7%
Operating income9101112136342.6B JPY in 2025+42% since 2018
0200.0B JPY400.0B JPY600.0B JPY2018: 241.8B JPY241.8B JPY20182019: 237.7B JPY237.7B JPY2019−2%2020: 100.4B JPY100.4B JPY2020−58%2021: 509.3B JPY509.3B JPY2021+407%2022: 460.8B JPY460.8B JPY2022−10%2023: 490.5B JPY490.5B JPY2023+6%2024: 214.1B JPY214.1B JPY2024−56%2025: 342.6B JPY342.6B JPY2025+60%
Net income9101112136108.1B JPY in 2025−42% since 2018
0100.0B JPY200.0B JPY300.0B JPY400.0B JPY2018: 186.7B JPY186.7B JPY20182019: 135.1B JPY135.1B JPY2019−28%2020: 44.3B JPY44.3B JPY2020−67%2021: 376.2B JPY376.2B JPY2021+749%2022: 230.2B JPY230.2B JPY2022−39%2023: 317.0B JPY317.0B JPY2023+38%2024: 144.2B JPY144.2B JPY2024−55%2025: 108.1B JPY108.1B JPY2025−25%

Every line of the income statement in the latest annual report, as filed.14

Period ending2026-03-312025-03-312024-03-31
Revenue4.5T JPY4.6T JPY4.3T JPY
Cost of sales-1.6T JPY-1.6T JPY-1.4T JPY
Selling, general and administrative expenses-1.1T JPY-1.1T JPY-1.1T JPY
Research and development expenses-675.9B JPY-730.2B JPY-729.9B JPY
Amortization and impairment losses on intangible assets associated with products-633.5B JPY-643.2B JPY-652.1B JPY
Other operating income24.7B JPY26.2B JPY19.4B JPY
Other operating expenses-559.0B JPY-206.7B JPY-206.5B JPY
Operating profit6.2B JPY342.6B JPY214.1B JPY
Finance income211.2B JPY46.5B JPY52.1B JPY
Finance expenses-357.6B JPY-210.1B JPY-219.8B JPY
Share of profit (loss) of investments accounted for using the equity method-2.2B JPY-4.0B JPY6.5B JPY
Profit (loss) before tax-142.4B JPY175.1B JPY52.8B JPY
Income tax (expenses) benefit-9.8B JPY-66.9B JPY91.4B JPY
Net profit (loss) for the year-152.1B JPY108.1B JPY144.2B JPY
Owners of the Company-152.4B JPY107.9B JPY144.1B JPY
Non-controlling interests264.0M JPY215.0M JPY130.0M JPY
Basic earnings (loss) per share (in JPY per share)-96.75 JPY68.36 JPY92.09 JPY
Diluted earnings (loss) per share (in JPY per share)-96.75 JPY67.23 JPY91.16 JPY

Compare Takeda Pharmaceutical Company with another company

The story

Founded by Takeda Chōbei I on Aug 1, 1781, in Doshōmachi.1

Leadership

Who has led Takeda Pharmaceutical Company, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (2)

Products and brands

  • Actos
  • Elvanse

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

  • Shire plc
  • Takeda
  • Takeda (Finland)
  • Takeda (Germany)
  • Takeda (Switzerland)
  • Takeda (United States)
  • Nycomed since Sep 2011

Also owns

From Wikidata.1

Acquisitions

  1. Sep 2011Acquired Nycomed1
  2. 2011Acquired Takeda (Finland)1

Timeline

  1. Aug 1, 1781Founded Founded in Doshōmachi1

Recent filings

  1. Sep 15, 20264
  2. Sep 14, 20266-K
  3. Sep 10, 2026144
  4. Sep 3, 20264
  5. Sep 2, 2026144
  6. Aug 31, 20266-K
  7. Aug 21, 20264
  8. Aug 19, 2026144
  9. Aug 19, 20264
  10. Aug 14, 2026144
  11. Aug 12, 20264
  12. Aug 12, 20264
  13. Aug 12, 20264
  14. Aug 12, 20264
  15. Aug 12, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Yahoo FinanceTAK quote
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15